The FDA for the first time is facing pharma-backed criticism of its new practice of publicly releasing partially redacted drug rejection letters. The law firm

Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds

RIPK1 is becoming a relative desert for large drugmakers. Eli Lilly has joined the exodus, ripping apart the remainder of its up to $960 million

The first recipients of the UK government’s £500 million Sovereign AI fund have been announced, including two life sciences-focused startups.

The first recipients of the UK government’s £500 million Sovereign AI fund have been announced, including two life sciences-focused start-ups.